Chronic low-dose L-NAME treatment effect on cardiovascular system of borderline hypertensive rats: Feedback regulation?

Neuroendocrinology Letters

Volumn 29, Issue 5, 2008, Pages 784-789

  Kopincová, Jana ^a   Púzserová, Angelika ^a   Bernátová, Iveta ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Blood pressure; Hypertrophy; Nitric oxide; Prehypertension; Vasorelaxation

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; BORDERLINE HYPERTENSIVE RAT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEEDBACK SYSTEM; FEMORAL ARTERY; LOW DRUG DOSE; MALE; MYOGRAPHY; NONHUMAN; RAT; TREATMENT DURATION; TREATMENT FAILURE; VASOCONSTRICTION; VASODILATATION;

EID: 57149142784     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Adler S, Huang H (2004). Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol. 287: F907-F913.
2. Aktan F (2004). iNOS-mediated nitric oxide production and its regulation. Life Sci. 75: 639-653.
3. Arnal JF, El Amrani AI, Chatellier G, Ménard J, Michel JB (1993). Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22: 380-387.
4. Arnal JF, Warin L, Michel JB (1992). Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 90: 647-652.
5. Assreuy J, Cunha FQ, Liew FY, Moncada S (1993). Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol. 108: 833-837.
6. Babál P, Pecháňová O, Bernátová I, Štvrtina S (1997). Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol. 12: 623-629.
7. Bernátová I, Kopincová J, Púzserová A, Janega P, Babál P (2007). Chronic low-dose L-NAME treatment increases nitric oxide production and vasorelaxation in normotensive rats. Physiol Res. 56 Suppl 2: S17-24.
8. Bernátová I, Pecháňová O, Babál P, Kyselá S, Štvrtina S, Andriantsitohaina R (2002). Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol. 282: H942-H948.
9. G-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol. 81: 99-106.
10. Bernátová I, Pecháňová O, Pelouch V, Šimko F (2000). Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol. 32: 177-185.
11. Bernátová, Pecháňová O, Šimko F (1999b). Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol. 84: 1095-1105.
12. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, et al (2003). Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med. 9: 68-75.
13. Buga GM, Griscavage JM , Rogers NE Ignarro LJ (1993). Negative feedback regulation of endothelial cell function by nitric oxide. Circ. Res. 73: 808-812.
14. Colasanti M, Persichini T, Menegazzi M, Mariotto S, Giordano E, Caldarera CM, et al (1995). Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. J Biol Chem. 270: 26731-26733.
15. Devlin AM, Brosnan MJ, Graham D, Morton JJ, McPhaden AR, McIntyre M, et al (1998). Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am J Physiol. 274: H52-H59.
16. Forstermann U, Boissel J-P, Kleinert H (1998). Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12: 773-790.
17. Gerová M, Kristek F (2001). Efficiency of NO donors in substituting impaired endogenous NO production: a functional and morphological study. Physiol Res. 50: 165-173.
18. Griscavage JM, Fukuto JM, Komori Y, Ignarro LJ (1994). Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group. Role of tetrahydrobiopterin in modulating the inhibitory action of nitric oxide. J Biol Chem. 269: 21644-49.
19. Griscavage JM, Hobbs AJ, Ignarro LJ (1995). Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol. 34: 215-234.
20. Grumbach IM, Chen W, Mertens SA, Harrison DG (2005). A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol.Cell Cardiol. 39: 595-603.
21. Guix FX, Uribesalgo I, Coma M, Munoz FJ (2005). The physiology and pathophysiology of nitric oxide in the brain Prog Neurobiol. 76: 126-152.
22. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, et al (1998). Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 83: 743-51.
23. Kojšová S, Jendeková L, Pecháňová O (2007): The time-dependent effect of L-NAME on endothelial NOS expression in the heart and brain. J Hypertens 25 (suppl 2): S257.
24. Lassegue B, Griendling KK (2004). Reactive oxygen species in hypertension; An update. Am J Hypertens. 17: 852-860.
25. Luss H, Disilvio M, Litton AL, Molina Y, Vedia L, Nussler AK, et al (1994). Inhibition of nitric oxide synthesis enhances the expression of inducible nitric oxide synthase mRNA and protein in a model of chronic liver inflammation. Biochem Biophys Res Commun. 204: 635-640.
26. Maes M, Mihaylova I, Kubera M, Bosmans E (2007). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuroendocrinol Lett. 28: 463-469.
27. Matsubara BB, Matsubara LS, Zornoff LA, Franco M, Janicki JS (1998). Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 93: 173-181.
28. Müller E, Kerschbaum HH (2006). Progesterone and its metabolites 5-dihydroprogesterone and 5-3-tetrahydroprogesterone decrease LPS-induced NO release in the murine microglial cell line, BV-2. Neuroendocrinol Lett. 27: 675-678.
29. Münzel T, Daiber A, Ullrich V, Mülsch A (2005). Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol. 25: 1551-1557.
30. Nakata S, Tsutsui M, Shimokawa H, Tamura M, Tasaki H, Morishita T, et al (2005). Vascular neuronal NO synthase is selectively up-regulated by platelet-derived growth factor: involvement of the MEK/ERK pathway. Arterioscler Thromb Vasc Biol. 25: 2502-2508.
31. Park SK, Lin HL, Murphy S (1997). Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. Biochem J. 322: 609-613.
32. Pecháňová O, Bernátová I, Pelouch V, Šimko F (1997). Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol. 29: 3365-3374.
33. Pečivová J, Mačičková T, Lojek A, Gallová L, Číž M, Nosár R, et al (2006). Effect of carvedilol on reactive oxygen species and enzymes linking innate and adaptive immunity. Neuroendocrinol Lett. 27 Suppl 2: 160-163.
34. Peng HB, Spiecker M, Liao JK (1998). Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol. 161: 1970-1976.
35. Púzserová A, Csizmadiová Z, Andriantsitohaina R, Bernátová I. (2006). Vascular effects of red wine polyphenols in chronic stress-exposed Wistar-Kyoto rats. Physiol Res. 55 Suppl 1: S39-S47.
36. Púzserová A, Csizmadiová Z, Bernátová I (2007). Effect of blood pressure on L-NAME-sensitive component of vasorelaxation in adult rats. Physiol Res. 56 Suppl 2: S77-S84.
37. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 101: 746-752.
38. Rogers NE, Ignarro LJ (1992). Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem Biophys Res Commun. 189: 242-249.
39. Sadoshima J, Izumo S (1993). Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 73: 413-423.
40. Sheffler LA, Wink DA, Melillo G, Cox GW (1995). Exogenous nitric oxide regulates IFN-gamma plus lipopolysaccharide-induced nitric oxide synthase expression in mouse macrophages. J Immunol. 155: 886-894.
41. Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin EL (1996). Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension. 27: 49-55.
42. Sylvester FA (1997). L-NAME-Induced Hypertension in the WKY and BHR rat (thesis). Des Moines, Iowa: Drake Univ.
43. Tucker EJ, Ledingham JM, Zheng Y, Laverty R (2000). Effects of chronic inhibition of nitric oxide synthase in the genetically hypertensive rat. Clin Exp Pharmacol Physiol. 27: 647-649.
44. Vaziri ND, Wang XQ (1999). cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 34: 1237-1241.
45. Zúrová-Nedelčevová J, Navarová J, Drábiková K, Jančinová V, Petríková M, Bernátová I, et al., (2006). Participation of reactive oxygen species in diabetes-induced endothelial dysfunction. Neuroendocrinol Lett. 27 Suppl 2: 168-171.